Loading...
•
Dec 31, 2021
Verrica Q4 2021 Earnings Report
Reported a net loss and focused on the potential launch of VP-102 and advancement of LTX-315.
Key Takeaways
Verrica Pharmaceuticals reported a net loss of $9.5 million for Q4 2021, compared to a $13.0 million loss for the same period in 2020. The company is preparing for the potential launch of VP-102 for molluscum and advancing LTX-315 for non-melanoma skin cancers.
Resubmitted the New Drug Application (NDA) for VP-102 for the treatment of molluscum contagiosum.
FDA acknowledged the resubmitted NDA and assigned a PDUFA goal date of May 24, 2022.
Expected to dose the first patient in the Phase 2 clinical trial of LTX-315 for basal cell carcinoma in Q1 2022.
Amended its existing $40 million credit facility to provide increased financial flexibility.
Forward Guidance
Verrica believes that its existing cash, cash equivalents, and marketable securities as of December 31, 2021 will be sufficient to support planned operations into the third quarter of 2022.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...